Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mark Yazer

Pittsburgh, PA Medical Doctor

NPI 1609842913 CMS profile 163038

200 Lothrop St, Pittsburgh, PA 15213

Open in the dashboard

General payments

$2,185,783

73 records reported · program years 2019–2025

Research payments

$1,920

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mark Yazer of Pittsburgh, PA is reported in the CMS Open Payments database as having received $2,185,783 across 73 general payments and $1,920 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $349,676 11
2024 General $403,456 21
2023 General $386,986 8
2022 General $220,360 13
2021 General $232,895 10
2020 General $381,376 6
2020 Research $1,200 1
2019 General $211,036 4
2019 Research $720 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Yazer
  • Pennsylvania median
  • Middle half of Pennsylvania
  • National median

In program year 2025, general payments to Mark Yazer were reported at $349,676. Among 44,217 Pennsylvania profiles paid that year, the median was $168 and the middle half received between $50 and $597.

Show as a table
Year Mark Yazer Pennsylvania median Middle half National median
2019 $211,036 $156 $46–$628 $163
2020 $381,376 $109 $33–$381 $114
2021 $232,895 $125 $35–$469 $132
2022 $220,360 $136 $40–$499 $149
2023 $386,986 $147 $46–$523 $160
2024 $403,456 $156 $46–$568 $164
2025 $349,676 $168 $50–$597 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Vitalant $1,949,489 56 payments
  2. Institute for Transfusion Medicine $208,951 1 payment
  3. Grifols, S.A. $18,233 10 payments
  4. Grifols Diagnostic Solutions, Inc. $5,300 2 payments
  5. Terumo BCT, Inc. $3,810 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,164,465 60 payments
  2. Consulting Fee $9,800 3 payments
  3. Travel and Lodging $6,155 8 payments
  4. Honoraria $5,300 1 payment
  5. Food and Beverage $63 1 payment
Products named General payments · program years 2019–2025
  1. Erytra Eflexis $5,300 2 payments
  2. Trima Accel $1,725 1 payment
  3. Spectra Optia Apheresis System $1,500 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Octapharma USA, Inc. $1,920 2 payments

Records

75 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record